Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.47 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.47 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.47 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.47 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.47 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | EP300 | Q09472 | 1/20 | 0.45 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CCR1 | P32246 | 1/20 | 0.43 |
| ▸ | CCR5 | P51681 | 1/20 | 0.43 |
| ▸ | CCR8 | P51685 | 1/20 | 0.43 |
| ▸ | METAP1 | P53582 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17104893 | 0.80 | RAB9A (0.55) | SMN1; SMN2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL3390634 | 0.80 | RAB9A (0.42) | SMN1; SMN2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL12075261 | 0.78 | POLB (0.50) | SMN1; SMN2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL31436278 | 0.77 | SMN1; SMN2 (0.42) | SMN1; SMN2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL14668905 | 0.77 | KDM4E (0.63) | SMN1; SMN2POLBRAB9AKDM4ELMNA | |
| SCHEMBL14416091 | 0.75 | GRM5 (0.47) | SMN1; SMN2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL23354966 | 0.74 | ALKBH2 (0.51) | SMN1; SMN2KDM4ELMNAP4HTMALKBH2 | |
| SCHEMBL12075529 | 0.72 | NPC1 (0.38) | SMN1; SMN2RAB9AKDM4EALDH1A1TDP1 | |
| SCHEMBL10930181 | 0.72 | SMN1; SMN2 (0.47) | SMN1; SMN2POLBEP300KAT2BRAB9A | |
| SCHEMBL21353591 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119638676-A | Nitrogen heteroaromatic ring modified dibromo-1, 3-di (1-butylimidazol-3-yl) benzene ligand and preparation method thereof, iridium complex and organic electroluminescent device | 清华大学深圳国际研究生院 | 2025-03-18 | — | — | CN | claimed |
| CN-119192180-A | Iridium complex of [3,2,1-de ] acridine-5, 9-diketo quinine ligand based on aza-aromatic ring modification and organic electroluminescent device | 清华大学深圳国际研究生院 | 2024-12-27 | — | — | CN | claimed |
| CN-115260201-A | Iridium complex based on nitrogen heterocyclic aromatic ring modified indolo [3,2,1-jk ] carbazole main ligand and application thereof | 马鞍山南大高新技术研究院有限公司 | 2022-11-01 | — | — | CN | claimed |
| US-20260085056-A1 | OX1 RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2026-03-26 | — | — | US | disclosed |
| CN-120590443-A | 2N-type manganese complex and preparation method thereof, and preparation method of phenyl alkyl disiloxane | 石河子大学 | 2025-09-05 | — | — | CN | disclosed |
| US-20250243194-A1 | ANTAGONIST OF ADENOSINE RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2025-07-31 | — | — | US | disclosed |
| US-12331029-B2 | Orexin 1 receptor antagonists | NXERA PHARMA UK LIMITED (GB) | 2025-06-17 | — | — | US | disclosed |
| CN-119638676-A | Nitrogen heteroaromatic ring modified dibromo-1, 3-di (1-butylimidazol-3-yl) benzene ligand and preparation method thereof, iridium complex and organic electroluminescent device | 清华大学深圳国际研究生院 | 2025-03-18 | — | — | CN | disclosed |
| US-12240825-B2 | Oxexin 1 receptor antagonists | NXERA PHARMA UK LIMITED (GB) | 2025-03-04 | — | — | US | disclosed |
| CN-119192180-A | Iridium complex of [3,2,1-de ] acridine-5, 9-diketo quinine ligand based on aza-aromatic ring modification and organic electroluminescent device | 清华大学深圳国际研究生院 | 2024-12-27 | — | — | CN | disclosed |
| US-20240132475-A1 | SUBSTITUTED PYRAZOLYL COMPOUNDS AS MALT-1 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2024-04-25 | — | — | US | disclosed |
| EP-2475653-A1 | SUSTITUTED ( HETEROARYLMETHYL ) THIOHYDANTOINS AS ANTICANCER DRUGS | Bayer Pharma Aktiengesellschaft (DE) | 2012-07-18 | — | — | EP | disclosed |
| US-8193223-B2 | 1,2,3-triazole derivatives as sigma receptor inhibitors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-06-05 | — | — | US | disclosed |
| WO-2011029537-A1 | SUSTITUTED ( HETEROARYLMETHYL ) THIOHYDANTOINS AS ANTICANCER DRUGS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-03-17 | — | — | WO | disclosed |
| US-20100004265-A1 | 1,2,3-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. | 2010-01-07 | — | — | US | disclosed |
| EP-2097392-A1 | 1,2,3-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-09-09 | — | — | EP | disclosed |
| WO-2008055933-A1 | 1,2,3-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-05-15 | — | — | WO | disclosed |
| EP-1921072-A1 | 1,2,3-Triazole derivatives as cannabinoid-receptor modulators | Laboratorios del Dr. Esteve S.A. (ES) | 2008-05-14 | — | — | EP | disclosed |
| EP-1921071-A1 | 1,2,3- triazole derivatives as sigma receptor inhibitors | Laboratorios del Dr. Esteve S.A. (ES) | 2008-05-14 | — | — | EP | disclosed |
| WO-2008022182-A1 | METHODS FOR PROMOTING COUPLING BETWEEN BONE FORMATION AND RESORPTION | THE UAB RESEARCH FOUNDATION (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004265-A1 | 1,2,3-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | SIGMAR1, OPRK1, OPRD1 | SMN1; SMN2 3802/4885GRIN2D 152/4885GRIN3B 71/4885 |
| US-12240825-B2 | Oxexin 1 receptor antagonists | HCRTR1, HCRTR2, OXTR | SMN1; SMN2 1892/4885GRIN2D 178/4885GRIN3B 114/4885 |
| US-20260085056-A1 | OX1 RECEPTOR ANTAGONISTS | CNR1, CNR2, OPRM1 | SMN1; SMN2 1044/4885GRIN2D 187/4885GRIN3B 296/4885 |
| US-20250243194-A1 | ANTAGONIST OF ADENOSINE RECEPTORS | ADORA2B, ADORA2A, ADORA1 | SMN1; SMN2 3476/4885GRIN2D 1137/4885GRIN3B 803/4885 |
| US-12331029-B2 | Orexin 1 receptor antagonists | HCRTR1, HCRTR2, NPY1R | SMN1; SMN2 2255/4885GRIN2D 213/4885GRIN3B 156/4885 |
| US-20240132475-A1 | SUBSTITUTED PYRAZOLYL COMPOUNDS AS MALT-1 INHIBITORS | MALT1, FKBP1B, FKBP1A | SMN1; SMN2 2342/4885GRIN2D 4505/4885GRIN3B 3784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.